Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
University of California San Diego
Not signed up.
Modeling the Diabetic Gut: how microbes fuel metabolic disorders
The prevalence of type II diabetes mellitus [T2DM] continues to increase worldwide. Growing evidence suggests that chronic systemic endotoxinemia due to gut microbiota and an impaired gut barrier plays a key role in the pathogenesis of a metabolic diseases. The gut mucosa maintains immune homeostasis under physiological circumstances by serving as a barrier that restricts access of trillions of microbes and diverse microbial products to the largest immune system in the body. The gut barrier is comprised of a single layer of epithelial cells, bound by cell-cell junctions; loosening of the junctions induced by stressors, compromises the gut barrier and allows microbes and antigens to leak through and encounter the host immune system, thereby generating systemic endotoxemia. An impaired gut barrier, i.e., ‘leaky gut’, is believed to be a major contributor to the initiation and/or progression of T2DM, obesity, and atherosclerosis. Microbes also control the secretion of glucagon-like peptide-1 (GLP-1) and peptide-2 (GLP-2), from intestinal L-cells which control glucose homeostasis and gut barrier function, respectively. This multidisciplinary proposal seeks to study the importance of a novel molecular mechanism, the stress-polarity pathway comprised of AMPK and GIV, which fortifies the gut barrier against stress-induced collapse; this pathway appears to be necessary and sufficient for the barrier-protective functions of metformin, the widely-prescribed anti-diabetic drug. Using organoid based Gut-in-a dish model we will determine the role of DM-associated microbes and microbial products in gut barrier and in the activation of the SPS- pathway in colonic enteroid-derived monolayers (EDMs) (AIM1). We will assess the impact of microbes, microbial products and nutritional components on the secretion of peptide hormones (PYY, GLP-1/2) that are secreted from the gut lining using intestinal EDMs (AIM2) Insights gained will expose how strengthening the gut barrier is a viable strategy to achieve glycemic control in the most challenging patients, and can serve as the front line of tackling metabolic syndrome and chronic diseases.
Drag a column header and drop it here to group by that column
Modeling the Diabetic Gut: how microbes fuel metabolic disorders (Das, Soumita)
View Progress Report Document
No uploaded documents found.
Year: 2020; Items: 1
The stress polarity signaling (SPS) pathway serves as a marker and a target in the leaky gut barrier: implications in aging and cancer.
Ghosh P, Swanson L, Sayed IM, Mittal Y, Lim BB, Ibeawuchi SR, Foretz M, Viollet B, Sahoo D, Das S
Life science alliance
, 2020 (3)
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Gastro-Intestinal (GI) Committee has the principal function of furthering the mission of the consortium with regard to diabetic gastro-intestinal (GI) and liver disease
Curation Flag Information
New comment to be added:
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!